US20050192428A1 - Mutated recombinant collagens - Google Patents
Mutated recombinant collagens Download PDFInfo
- Publication number
- US20050192428A1 US20050192428A1 US10/720,831 US72083103A US2005192428A1 US 20050192428 A1 US20050192428 A1 US 20050192428A1 US 72083103 A US72083103 A US 72083103A US 2005192428 A1 US2005192428 A1 US 2005192428A1
- Authority
- US
- United States
- Prior art keywords
- site
- collagen
- procollagen
- recombinant
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000008186 Collagen Human genes 0.000 title claims abstract description 130
- 108010035532 Collagen Proteins 0.000 title claims abstract description 130
- 229920001436 collagen Polymers 0.000 title claims abstract description 130
- 108010050808 Procollagen Proteins 0.000 claims abstract description 117
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 65
- 230000002797 proteolythic effect Effects 0.000 claims abstract description 62
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 21
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 20
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 20
- 108091005804 Peptidases Proteins 0.000 claims abstract description 11
- 239000013598 vector Substances 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 239000004365 Protease Substances 0.000 claims abstract description 8
- 238000013518 transcription Methods 0.000 claims abstract description 7
- 230000035897 transcription Effects 0.000 claims abstract description 7
- 230000001105 regulatory effect Effects 0.000 claims abstract description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims abstract 2
- 210000004027 cell Anatomy 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 26
- 210000004899 c-terminal region Anatomy 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 239000000758 substrate Substances 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 210000004748 cultured cell Anatomy 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 230000003190 augmentative effect Effects 0.000 claims description 2
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 230000007073 chemical hydrolysis Effects 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000003416 augmentation Effects 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 2
- 230000017854 proteolysis Effects 0.000 abstract description 2
- 239000002299 complementary DNA Substances 0.000 description 37
- 238000003776 cleavage reaction Methods 0.000 description 29
- 230000007017 scission Effects 0.000 description 29
- 239000012634 fragment Substances 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102000035195 Peptidases Human genes 0.000 description 9
- 239000002773 nucleotide Substances 0.000 description 9
- 125000003729 nucleotide group Chemical group 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000012545 processing Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 108010013369 Enteropeptidase Proteins 0.000 description 6
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 6
- 102000044159 Ubiquitin Human genes 0.000 description 6
- 108090000848 Ubiquitin Proteins 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 102100029727 Enteropeptidase Human genes 0.000 description 5
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 5
- 108010049937 collagen type I trimeric cross-linked peptide Proteins 0.000 description 5
- 230000008602 contraction Effects 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 210000004872 soft tissue Anatomy 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 101800001415 Bri23 peptide Proteins 0.000 description 4
- 101800000655 C-terminal peptide Proteins 0.000 description 4
- 102400000107 C-terminal peptide Human genes 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000005094 computer simulation Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 230000009261 transgenic effect Effects 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 102100036213 Collagen alpha-2(I) chain Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000875067 Homo sapiens Collagen alpha-2(I) chain Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- LOJFGJZQOKTUBR-XAQOOIOESA-N NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCC(O)=O)C)CC1=CN=CN1 LOJFGJZQOKTUBR-XAQOOIOESA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 102000013373 fibrillar collagen Human genes 0.000 description 3
- 108060002894 fibrillar collagen Proteins 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 235000019419 proteases Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 2
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010069502 Collagen Type III Proteins 0.000 description 2
- 102000001187 Collagen Type III Human genes 0.000 description 2
- 102000004266 Collagen Type IV Human genes 0.000 description 2
- 108010042086 Collagen Type IV Proteins 0.000 description 2
- 108010022514 Collagen Type V Proteins 0.000 description 2
- 102000012432 Collagen Type V Human genes 0.000 description 2
- 108010034789 Collagen Type XI Proteins 0.000 description 2
- 102000009736 Collagen Type XI Human genes 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940096422 collagen type i Drugs 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000001323 posttranslational effect Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 230000006337 proteolytic cleavage Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 108010016264 ubiquitin-Nalpha-protein hydrolase Proteins 0.000 description 2
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241001156002 Anthonomus pomorum Species 0.000 description 1
- BXTVQNYQYUTQAZ-UHFFFAOYSA-N BNPS-skatole Chemical compound N=1C2=CC=CC=C2C(C)(Br)C=1SC1=CC=CC=C1[N+]([O-])=O BXTVQNYQYUTQAZ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102220478107 Myc box-dependent-interacting protein 1_H64A_mutation Human genes 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- 101800000021 N-terminal protease Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010041520 Pulmonary Surfactant-Associated Proteins Proteins 0.000 description 1
- 102000000528 Pulmonary Surfactant-Associated Proteins Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 241000220010 Rhode Species 0.000 description 1
- 101100036900 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL40A gene Proteins 0.000 description 1
- 206010039580 Scar Diseases 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108090000787 Subtilisin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100028644 Tenascin-R Human genes 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 101150106669 UBI1 gene Proteins 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000035557 fibrillogenesis Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- IFPHDUVGLXEIOQ-UHFFFAOYSA-N ortho-iodosylbenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I=O IFPHDUVGLXEIOQ-UHFFFAOYSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 108010079892 phosphoglycerol kinase Proteins 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 108010094020 polyglycine Proteins 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 108010020387 tenascin R Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000008791 toxic response Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/20—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from milk, e.g. casein; from whey
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/04—Animal proteins
- A23J3/06—Gelatine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C2230/00—Aspects relating to animal feed or genotype
- A23C2230/05—Milk or milk products from transgenic animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the field of this invention is recombinant procollagens containing novel cleavage sites.
- Collagen has provided a number of commercial applications including use as a convenient substrate for cell culture, as well as in the manufacture of biocompatible materials (e.g., artificial skin) having a variety of therapeutic applications in humans.
- Commercially available collagens are primarily isolated from freshly killed farm animals (e.g., cows, pigs, chickens) in polymerized form or in soluble form derived by enzymatic or chemical treatment of polymerized collagen.
- polymerized collagens, and soluble collagens derived from polymerized collagens are of limited usefulness due to the presence of natural crosslinks within the collagen.
- non-human collagens can provoke undesirable immune responses when administered to human subjects.
- human collagen can be purified from human sources such as human placenta, as described in U.S. Pat. No. 5,002,071 (Research Development Foundation) and in copending U.S. application Ser. No. 07/921,810 (Collagen Corporation).
- human sources such as human placenta
- U.S. Pat. No. 5,002,071 Search Development Foundation
- U.S. application Ser. No. 07/921,810 Cold-tosese, Y.
- the methods for recovering collagen from these sources bias the type of collagen recovered.
- collagen is derived from naturally crosslinked tissues, the collagen recovered is not entirely homogenous.
- Another approach to the production of human collagen is the expression of recombinant human collagen in the milk of transgenic animals, as described in copending U.S. application Ser. Nos. 08/183,648 and 08/011,643 (Collagen Corporation).
- this approach subjects the recombinant collagen to any host deficiencies in translational processing.
- collagen refers to a type of protein that encompasses a class of structurally related polypeptides consisting of helical collagen chains and homo- and heteromeric polymers thereof.
- Collagen chains often contain both long helical domains and non-helical extensions, or telopeptides.
- the helical domains comprise -(GXY) n — repeats, where X and/or Y are frequently proline or hydroxyproline.
- Collagen polypeptide chains are encoded by a number of related genes, See, Adams, S. L. Amer J Respir Cell and Mol Biol (1989) 1:161-168; Mayne and Brewton (1993) Current Opinion in Cell Biology 5:883-890; van der Rest and Bruckner (1993) Current Opinion in Structural Biology 3:430-436.
- Collagen-encoding transcripts are initially translated into procollagen chains which undergo a variety of post-translational events such as processing, secretion and assembly (e.g. disulfide exchange, prolyl residue hydroxylation, glycosylation, and crosslinking of the helical chains; see, for example, Prockop et al.
- procollagens contain N- and C-terminal propeptides that facilitate collagen formation. See, for example, Lee et al. (1992) J Biol Chem 267, 24126-24133.
- procollagen propeptides are cleaved from the procollagens by tissue-specific procollagen N- and C-terminal proteases. Accordingly, recombinant production of collagen has been severely restricted by the inability of conventional cellular expression systems to efficiently post-translationally modify procollagen to form functionally mature collagen.
- the invention provides recombinant procollagen chains having a natural collagen polypeptide chain separated from a propeptide by a non-natural site-specific proteolytic agent recognition site (i.e. the site is not naturally present at that location of a natural procollagen chain).
- the propeptide is often a C-terminal propeptide and, frequently, a natural procollagen C-terminal propeptide.
- the recombinant procollagen chains may further comprise a second propeptide separated from the opposite end of the natural collagen chain by a second non-natural site-specific proteolytic agent recognition site.
- propeptides and site-specific proteolytic agent recognition sites may be used.
- the propeptide is capable of increasing the yield of at least one of secreted procollagen (trimeric procollagen chains) or collagen monomers (trimeric collagen chains) from cells expressing procollagen chains comprising the propeptide, as compared with cells expressing the same collagen chains alone, without the propeptide.
- the non-natural site-specific proteolytic agent recognition site is generally selected to provide a substrate for a convenient site-specific proteolytic agent.
- the agent is commonly a protease or a chemical agent which selectively cleaves at accessible and preferentially labile peptide bonds. Where two site-specific proteolytic agent recognition sites and two propeptides are present, the recognition sites may have the same or different amino acid sequences with the same or different site-specific proteolytic agent affinities and specificities.
- the subject procollagen chains may be constructed such that the site-specific proteolytic agent cleavage site is a peptide bond that separates the collagen chain and/or the propeptide from the remainder of the procollagen chain.
- the cleavage site may be a peptide bond that separates, from the remainder of the procollagen chain, the collagen chain (or propeptide) joined to at least one amino acid which is not naturally present at that location of a natural collagen chain (or propeptide).
- the invention provides collagens produced by contacting the subject recombinant procollagen with site-specific proteolytic agents capable of selectively cleaving the procollagen chains at the site-specific proteolytic agent recognition sites, wherein the resulting chains comprise terminal peptides which may have non-natural amino acid sequences (i.e. not naturally present at that location of a natural collagen chain).
- the resulting collagen may be employed directly (e.g. to coat cell culture dishes or cultureware) or further polymerized and/or provided in sterile, nontoxic, biocompatible collagen compositions suitable for administration to humans.
- the invention also provides nucleic acids encoding the subject procollagen chains, as well as vectors and cells comprising such nucleic acids operably linked to transcription regulatory elements not naturally linked to such nucleic acids.
- the invention provides processes for the production of recombinant procollagen and/or collagen chains in and from such cells.
- the invention also provides methods of utilizing the resulting procollagen and collagen, for example, coating cultureware and augmenting localized tissue in a host by, for example, subcutaneous administration.
- FIG. 1 shows a three-dimensional computer model of the N-terminal propeptide-telopeptide region of human procollagen type I (a triple helix of two ⁇ 1 chains and one ⁇ 2 chain).
- the structure was produced on a Silicon Graphics workstation using Biosym software.
- the energy minimized structure is produced after manual chain pull-ins to speed the process of computing the energy minimums. Points of cleavage with N-pro-peptidase are marked with a “ ⁇ ”.
- FIG. 2 shows a three-dimensional computer model of the C-terminal propeptide-telopeptide region of human procollagen type I (a triple helix of two ⁇ 1 chains and one ⁇ 2 chain).
- the structure was produced on a Silicon Graphics workstation using Biosym software.
- the energy minimized structure is produced after manual chain pull-ins to speed the process of computing the energy minimums. Points of cleavage of the extra-helical peptide from the C-terminal pro-region are marked with a “ ⁇ ”. In the two ⁇ 1 chains, this is before Gly 38; in the ⁇ 2 chain, it is before Glu 27.
- FIG. 3 shows a three-dimensional computer model of the N-terminal propeptide-telopeptide region of a mutant human procollagen type I containing the DDDK insertion.
- the structure was produced on a Silicon Graphics workstation using Biosym software.
- the energy minimized structure is produced after manual chain pull-ins to speed the process of computing the energy minimums.
- the insertional loop members are marked with a “ ⁇ ”.
- FIG. 4 shows the proteolytic cleavage site of the mutant human procollagen type I containing the DDDK insertion. Points of cleavage of N-propeptidase are marked with a “ ⁇ ”. Regions in whichc the ⁇ 1 chains are “coiled” are disignated with a “10”.
- the invention provides recombinant procollagen chains comprising a natural collagen chain, a propeptide, and a non-natural site-specific proteolytic agent recognition site (i.e. not naturally present at that location of a natural collagen chain) located between the collagen chain and the propeptides.
- the propeptide increases the yield of at least one of secreted procollagen (trimeric procollagen chains) or collagen monomers (trimeric collagen chains) recoverable from cells expressing the subject recombinant procollagen chains, as compared with cells expressing the collagen chains alone, without the propeptide.
- the yield is enhanced by at least 50%, preferably at least about 100%, more preferably at least about 200%, and most preferably at least about 1,000% in at least one expression system.
- Collagen refers to a variety of helical arrays of collagen chains and includes both polymerized and monomeric collagen.
- the propeptides are believed to improve collagen and/or procollagen yields by facilitating or increasing at least one of proper expression, processing, secretion, or polymerization of the procollagen chain, the collagen chain, and/or a collagen monomer.
- the function of the propeptide is readily monitored by comparing the yields of recoverable collagen and/or procollagen with and without the presence of the propeptide in in vitro or in vivo expression systems including lysates, transformed or transfected cells (such as mammalian cells or yeast), transgenic animals, etc. Specific examples of assays for propeptides are described below.
- the propeptide may take a wide variety of forms and sizes: it may be a natural procollagen propeptide, or a propeptide not naturally present as a propeptide in a procollagen chain, as long as it provides the procollagen with the requisite collagen yield. Generally, propeptides are at least 10, preferably at least about 25, more preferably at least about 75, and most preferably at least about 200 amino acids in length. The propeptide is generally located at the C-terminus or N-terminus of the procollagen chain, or the procollagen chain may have propeptides at both termini. Where the recombinant procollagen chains contain both C- and N-terminal propeptides, the chains often comprise a second (and often non-natural) site-specific proteolytic agent recognition site located between the collagen chain and the second propeptide.
- Preferred procollagen chains comprise at least a C-terminal propeptide, frequently a natural C-terminal portion of a protein with collagen-like repeats and/or a helical, especially triple-helical, polymeric form, such as complement protein C1q-C, acetocholine esterase, or lung surfactant protein.
- natural procollagen C-terminal propeptides such as collagen Type I, II, III, IV, V and XI C-terminal propeptides.
- Preferred N-terminal propeptides comprise at least one globular domain and often consist essentially of a single globular domain.
- natural procollagen N-terminal propeptides such as collagen type I, II, III, IV, V, and XI N-terminal propeptides.
- the propeptides are preferably purified out of the collagen composition.
- the propeptides are preferably selected such that, if small quantities of the propeptides remain in the collagen composition after processing, the residual propeptides do not interfere with the intended application of the resulting composition.
- the composition should not contain contaminants present in an amount sufficient to cause a toxic or immunogenic response or reaction in the patient.
- the recognition site is non-natural to a natural procollagen chain, meaning that the site occupies a portion of the procollagen chain not naturally occupied by the recognition site. Frequently, the site is not naturally present anywhere in the natural counterpart of the procollagen chain.
- the site generally comprises one or more amino acid residues or derivatives thereof.
- the recognition site may comprise a modified (e.g., methylated) residue, especially for some chemical proteolytic agents.
- These sites are selected to provide substrates for at least one convenient site-specific proteolytic agent, preferably a commercially available site-specific proteolytic agent.
- the precise site selection will depend on the selected expression system, the selected propeptide, and the availability of the site-specific proteolytic agent.
- the site should provide a highly selective target for the selected site-specific proteolytic agent, such that the target site (or both target sites) is cleaved while minimizing hydrolysis of peptide bonds within the collagen chain.
- a large number of site-specific proteolytic agents and their recognition sites are known and/or commercially available. See, for example, Carter (1990, supra), Saito et al. (1987) J. Biochem 101, 123-134, etc.
- chemical cleavage agents and their recognition sites are known, e.g. hydroxylamine: N ⁇ G; formic acid: D ⁇ P; acetic acid: D ⁇ P; cyanogen bromide: M ⁇ ; BNPS-skatole: W ⁇ ; o-iodosobenzoic acid: W ⁇ ; N-chlorosuccinimide: W ⁇ ; etc.
- natural or synthetic proteases e.g. catalytic antibodies, etc. may be used.
- proteases and their recognition sites include: chymotrypsin: W ⁇ and Y ⁇ and F ⁇ ; collagenase: P-X ⁇ G-P, endoproteinase Lys-C: K ⁇ ; enterokinase: D-D-D-K ⁇ (SEQ ID NO: 1:), Factor X a : I-E-G-R ⁇ (SEQ ID NO:2:); kallikrein: P—F—R ⁇ ; renin: Y-I-H—P—F—H-L ⁇ L (SEQ ID NO:3:), H64A subtilisin BPN: A-A-H—Y ⁇ (SEQ ID NO:4:), thrombin: R-G-P—R ⁇ ( SEQ ID NO:5:); trypsin: R ⁇ and K ⁇ ; ubiquitin protein peptidase: ubiquitin ⁇ ; etc.
- a wide variety of methods may be used to increase the efficiency of cleavage at a target site (e.g. the provision of flanking poly-glycine peptides to enhance accessibility) and/or to reduce non-target site cleavage (e.g. optimizing concentration ratios and reaction conditions).
- Preferred site/site-specific proteolytic agent combinations yield a collagen product that is conveniently adapted to the ultimate intended application.
- any residual non-natural terminal residues should not interfere with and, preferably, enhance the performance (e.g. the promotion of cell growth or adherence to coated cultureware) of the resulting collagen product vis-a-vis the natural collagen counterpart.
- the resulting collagen should not be immunologically reactive in the host from which the collagen chain is derived.
- immunological non-reactivity is effected by minimizing the number of non-collagen chain amino acid residues which remain joined to the collagen chain after site-specific proteolytic agent cleavage.
- Preferred site/site-specific proteolytic agent combinations yield collagen chains with fewer than 75, preferably fewer than 25, more preferably fewer than 10, most preferably fewer than 5 and, especially, zero, non-natural collagen chain terminal amino acid residues.
- preferred sites and site-specific proteolytic agents provide cleavage at or near the junction with natural collagen chain residues.
- the site-specific proteolytic agent recognition sites may have the same or different amino acid sequences, with the same or different site-specific proteolytic agent affinities and specificities.
- the site-specific proteolytic agent recognition site(s) generally, but need not, abut both the collagen chain and respective propeptide; i.e. the subject procollagen chains may also have a natural or non-natural (i.e. not naturally present at that location of a natural procollagen chain) amino acid sequence between the site-specific proteolytic agent recognition site and the collagen chain, and/or between the site-specific proteolytic agent recognition site and the propeptide.
- the resulting (after cleavage) recombinant collagen chains may comprise one or both terminal peptides having a non-natural amino acid sequence.
- the invention provides recombinant collagen chains produced by contacting the subject recombinant procollagen chains with site-specific proteolytic agents capable of selectively cleaving the procollagen chain at site-specific proteolytic agent recognition sites.
- Useful collagen compositions produced by such methods may retain residual site-specific proteolytic agents, wherein the site-specific proteolytic agents are present at concentrations that may exceed 1 picogram, frequently exceed 1 nanogram, and more frequently exceed 1 microgram per gram of collagen protein.
- Resulting collagen compositions may be subjected to conditions known in the art to be conducive to higher-order polymerization of the collagen, for example, fibril formation.
- Monomeric or polymeric collagen compositions may be further subjected to a wide variety of manipulations depending on the intended application.
- the collagen may be diluted in an solvent for optimal adsorption to solid substrates (e.g. glass or plastics such as polystyrene, polyethylene, polypropylene, acetate, nylon, etc.) useful in tissue or cell culture, or purified and sterilized (e.g. filter sterilization) for use in vivo, such as for tissue augmentation.
- solid substrates e.g. glass or plastics such as polystyrene, polyethylene, polypropylene, acetate, nylon, etc.
- purified and sterilized e.g. filter sterilization
- the invention provides nucleic acids encoding the subject recombinant procollagen chains. These nucleic acids may have a wide variety of forms and sizes and frequently comprise non-coding sequences which facilitate transcription of the encoded procollagen chains. Constructs comprising such nucleic acids operably linked to transcription regulatory elements are spliced into replication and/or transfection vectors, which are then used to transfect/transform cells.
- Nucleic acids encoding the collagen chain portions e.g. collA1, col1A2 and col3A1
- the site-specific proteolytic agent recognition portions of the subject nucleic acids are readily available, for example, through published sequences, including electronic databases (e.g., Genbank, the National Center for Biotechnology Information at the National Library for Medicine, etc.), through commercial vendors, through library hybridization with otherwise available collagen-encoding nucleic acids, or through known molecular cloning techniques.
- Materials and methods for constructing (e.g., recombinantly or synthetically) the subject procollagen-encoding nucleic acids, expression vectors, transformed and transfected cells, processes for producing a recombinant procollagen chain including selection from a wide variety of cells, e.g., cultured mammalian cells such as fibroblasts, CHO cells, yeast, mammary gland cells of transgenic mammals, etc.), transfecting/transforming and culturing the cells under conditions suitable for the expression of the nucleic acid, and recovering and purifying recombinant procollagen chains are disclosed herein or otherwise known in the art.
- construct design is effected by first preparing a three-dimensional model of a procollagen helix at the propeptide-telopeptide junction, then introducing amino acid substitutions that would allow cleavage with specific proteolytic enzymes.
- FIGS. 1 and 2 depict the structures of the N- and C-terminal propeptide-telopeptide regions of human type I procollagen, respectively. The structures are energy minimized and the native cleavage sites are marked. Molecular modeling is performed to ensure that the substitutions do not disrupt the folding of this region so as to inhibit processing, secretion, helical formation, or site-specific proteolytic agent accessibility.
- Molecular constructs are then generated by either mutating procollagen-encoding cDNAs or splicing nucleic acids encoding the selected collagen chain with nucleic acids encoding the selected site-specific proteolytic agent recognition site. Mutation may be effected by site-directed mutagenesis, nucleotide insertion or substitution (e.g., by PCR-based mutagenesis) or replacement of oligonucleotides by cloning.
- the insertion site is preferably at or within 100, preferably within 30, more preferably within 10 nucleotides distal to the procollagen site-specific proteolytic agent cleavage site encoding sequence.
- the substituted nucleotides are within 60, preferably within 36, preferably within 18, nucleotides distal to the procollagen site-specific proteolytic agent cleave site encoding sequence.
- Preferred constructs additionally comprise nucleic acids including a promoter region necessary for the expression of the encoded procollagen in an appropriate host.
- Preferred promoters that are constitutive in cultured cells include cytomegalovirus (CMV), simian virus (SV), and Rous sarcoma virus (RSV) promoters.
- Preferred promoters for tissue-specific expression (e.g., in mammary gland cells) of transgenic animals include casein or acid whey protein promoters.
- Preferred promoters for expression in yeast include phosphoglycerol kinase (PKG), alcohol dehydrogenase (ADH), and galactose (GAL).
- the construct is then transfected into and expressed in a cellular expression system, preferably an expression system wherein the mutated procollagen is secreted.
- the recombinant PROcollagen is not sufficiently secreted, and recovery entails lysing the cells and centrifuging the lysate to remove cellular debris.
- the cells are selected or engineered to express both the recombinant procollagen and a site-specific proteolytic agent capable of specifically cleaving the procollagen at the recognition site.
- the appropriate site-specific proteolytic agents are introduced in an amount sufficient to cleave the propeptides from the procollagen molecules prior to fibrillogenesis in the processing steps.
- Collagen chains are purified from the medium by methods known in the art. See, for example, Miller and Rhodes (1982) Methods in Enzymology 82:33-64; Sage and Bernstein (1982) Methods in Enzymology 82:96-127.
- Resulting collagen compositions may be sterilized, for example, by passage through 0.2 ⁇ m filters, (e.g., Millipore filters). Sterility may be confirmed by, for example, culturing aliquots on nutrient agar for at least 72 hours at 25 and 37° C.
- the invention provides a wide variety of applications of the subject recombinant procollagens and collagens in tissue and cell culture and therapy.
- the subject procollagens and collagens are used to promote adhesion and growth of cells on a wide variety of solid substrates in various forms, such as slides, filaments, sheets, plates, flasks, bottles, fibers, etc., and compositions such as plastics, glass, metals, saccharide-based polymers, etc.
- the collagens provide a wide range of therapeutic applications such as use in biodegradable sutures, synthetic dermal skin, biodegradable hemostatic sponges, tissue augmentation (including modifying localized soft tissue appearance), etc.
- FIGS. 1 and 2 depict the energy minimized structures of the N- and C-terminal propeptide/telopeptide regions of human type I procollagen, respectively. Substitutions were then inserted at the N-terminal cleavage junction site to generate a non-natural site-specific proteolytic agent recognition site and new models prepared to determine their affects on procollagen folding.
- FIG. 3 depicts an N-terminal fragment containing a DDDK (SEQ ID NO:1:) insertion in all three chains, introducing a recognition and cleavage site for enterokinase into the propeptide-telopeptide junction region.
- the proteolytic cleavage site of this mutant is particularly accessible in the energy-minimized structure.
- a cDNA clone containing the entire coding region of human ⁇ 1(I) procollagen is obtained from the Whitehead Institute (Cambridge, Mass.). The description of the cDNA is described in Stacy, et al, J Virol. 61: 2549 (1987). The nucleotide sequence of this clone (pHUC) is described in Tromp, et al, Biochem. J. 253:919 (1988), and also under Accession No. X07884 (Genbank, Los Alamos, N.Mex.). A cDNA clone (pSTL14) containing the entire coding region of human ⁇ 2(I) procollagen is described in Lee, et al, J. Biol. Chem.
- a specialized cloning vector (pPL1) is created by isolating the AflIII/SspI region of Bluescript II KSM13+ from nucleotide position 1153 to 2850 (Stratagene Cloning Systems, La Jolla, Calif.) and inserting a double-stranded deoxyoligonucleotide polylinker containing the restriction sites (in order) HindIII, PvuII, DraIII, and BamHI.
- a 618 nt region of the 5′ end of the cDNA is amplified by the Polymerase Chain Reaction (Perkin Elmer Cetus, Norwalk, Conn., according to the manufacturer's instructions) using the oligodeoxynucleotide primer #1 ACGCCAAGCTTGGCTGCAGGTCGA (SEQ ID NO:22:) and primer #2 pCTGTTTATCATCGTCGGGAGCAAAGTTTCCTCC (SEQ ID NO:23:).
- the underlined nucleotide sequence in primer #2 codes for the amino acid recognition site (DDDK) (SEQ ID NO:1:) for the proteolytic enzyme enterokinase.
- the 610 nt DNA fragment generated by the PCR reaction is cleaved with the restriction enzyme HindIII, and cloned into pPL1 at the HindIII/PvuII sites, creating pPL1-1.
- the PvuII/DraIII fragment from the human ⁇ 1(I) procollagen cDNA (nt 858 to nt 1797) is cloned into pPL1-1 at the PvuII/DraIII sites, creating pPL1-2.
- the next step is to insert the PvuII/PvuII (nt 569 to nt858) fragment of the human ⁇ 1(I) procollagen cDNA into pPL1-2 at the PvuII site, creating pPL1-3.
- This PvuII/PvuII fragment inserts itself into the vector in either orientation, so clones which contain the orientation identical to the human ⁇ 1(I) procollagen cDNA are identified by DNA sequence analysis following the manufacturer's protocol (using SequenaseTM DNA sequencing kit by U.S. Biochemicals, Cleveland, Ohio, and the deoxynucleotide GAGTCACCCACCGACCAAGA (SEQ ID NO:24:) as the primer).
- the cDNA fragment from the human ⁇ 1(I) procollagen cDNA from the DraIII site at position 1797 to the BamHI site at position 2886 is cloned into pPL1-3 at the DraIII/BamHI site, creating pPL1-4.
- the product of these steps is the continuous region of the human ⁇ 1(I) procollagen cDNA from the 5′ end of the cDNA to the BamHI site at position 2886 with the introduction of a coding region for the amino acids DDDK, which is the amino acid recognition site for enterokinase.
- pPL2 Another specialized cloning vector (pPL2) is created by the following procedure described above, but using a polylinker which contains the recognition sites for the restriction enzymes (in order) SalI, HindIII, BamHI, BspEII, and SspI.
- a fragment of the human ⁇ 1(I) procollagen cDNA from the BamHI site at position 2886 to the BspEI site at position 3817 is cloned into the vector at the BamHI/BspEI site, creating pPL2-1.
- pPL2-1 is digested with the restriction enzymes Eco47III and XhoI, and the 106 bp fragment is discarded.
- a double-stranded deoxyoligonucleotide with the sequence GCTGGTTTCGACTTCAGCTTCCTCCC CCAGCCACCTCAAGAGAAGGCTCACGATGGTGGC CGCTACTACCGGGCTTGGGATGATGCCAATGTGGTTCGTGACCGTGACC (SEQ ID NO:25:) is inserted into pPL2-1 at the Eco47III/XhoI site, creating pPL2-2.
- This double-stranded deoxyoligonucleotide contains three additional (underlined) deoxynucleotides (as compared to the human ⁇ 1(I) procollagen cDNA in this region) which code for the amino acid tryptophan.
- a fragment of the human ⁇ 1(I) procollagen cDNA from nt 3818 to 4611 is removed by the restriction enzymes BspEI and SspI and inserted into pPL2-2 at the BspEI/SspI site, creating pPL2-3.
- the human ⁇ 1(I) procollagen cDNA containing additional nucleotide sequences within the cDNA, which code for additional amino acid(s) at the N-terminal propeptide-telopeptide and C-terminal telopeptide-propeptide junctions, is created by removal of the HindIII/BamHI fragment from pPL1-4 containing the 5′ region of the human ⁇ 1(I) procollagen cDNA, as described in section B above, and inserting this fragment into the HindIII/BamHI sites of pPL2-3 containing the 3′ region of the human ⁇ 1(I) procollagen cDNA, creating pM ⁇ 1(I).
- a specialized cloning vector (pPL3) is created as described in section B, but using a polylinker which contains the restriction sites (in order) SaII, SphI, PmII, MscI, and Sse83871.
- the human ⁇ 2(I) procollagen cDNA is excised from pSTL14 using SphI and SmaI restriction enzymes.
- the resulting DNA fragment is treated with T4 DNA polymerase in the presence of deoxynucleotides to make a blunt end at the 5′ end of the cDNA. This fragment is subcloned into the Bluescript II vector at the EcoRV and Smal sites.
- the ⁇ 2(I) procollagen cDNA fragment inserts itself into the vector in either orientation, so clones in which the Smal site is reconstituted are selected and given the name of p ⁇ 2(I) .
- Polymerase Chain Reaction is performed according to the manufacturer's instructions (Perkin Elmer Cetus, Norwalk, Conn.) using Saccharomyces cerevisiae genomic DNA as template and the phosphorylated deoxyoligonucleotides pGTGGTATGCAAATTTTTGTCAAGACTTTGACTG (SEQ ID NO:26:) and pCCACCTCTCAATCTCAAGACT (SEQ ID NO:27:) as primers to isolate a fragment of the yeast gene UBI1 (ubiquitin) described in Oezkaynak et al, EMBO J.
- the 232 bp DNA fragment is subcloned into the vector at the PmlI/MscI site, creating pPL3-1. This fragment inserts itself into the vector in either orientation, such that clones which contain the orientation identical to that of the human ⁇ 2(I) procollagen cDNA are identified by digestion with the restrictin enzymes PmlI and MscI.
- a second PCR reaction is performed using p ⁇ 2(I) DNA as the template and the two deoxyoligonucleotides pCCAGTATGATGGAAAAGGAGTT (SEQ ID NO:28:) and CGAGCACCTGCAGGACCAGTT (SEQ ID NO:29:) as the primers for this reaction.
- the 159 bp DNA fragment is digested with Sse83871 and subcloned into pPL3-1 at the MscI/Sse83871 sites, creating pPL3-2.
- p ⁇ 2(I) is digested with SalI and PmlI, and the 199 nt fragment is isolated and inserted into pPL3-2 at the SalI and PmlI sites, creating pPL3-3.
- p ⁇ 2(I) is digested with SalI and Sse8387I, and the 475 bp fragment is discarded.
- pPL3-3 is digested with SalI and Sse83871, and the 600 bp DNA fragment is isolated and cloned into p ⁇ 2(I) at the SalI and Sse83871 sites, creating pPL3-4.
- the human ⁇ 2(I) procollagen can be cleaved at the N-propeptide-N-telopeptide junction with a ubiquitin-specific processing protease, as described in Tobias and Varshavsky, J. Biol. Chem. 266: 12021 (1991).
- ⁇ 2(I) is digested with AvrII and EcoRI, and the 909 bp DNA fragment is discarded.
- Polymerase Chain Reaction is performed according to the manufacturer's instructions using p ⁇ 2(I) as template and the deoxyoligonucleotides TGGTCCTAGGGGCCCTGCTGGTCCTT (SEQ ID NO:30:) and pTCTACCTTCTATAGCCCTGTAGAAGTCTCCATCGTA (SEQ ID NO:31:) as primers.
- the underlined nucleotide sequence in the second primer codes for the amino acid recognition site (IEGR) (SEQ ID NO:02:) for Factor X a
- IEGR amino acid recognition site
- a second PCR reaction is performed using RT-PCR according to the manufacturer's instructions (Perkin Elmer Cetus, Norwalk, Conn.) using as template total RNA isolated from mouse spleen by the procedure of Han, et al, Biochem. 26, 1617 (1987). Random hexamers are used as primers for the reverse transcription of mouse RNA.
- the two PCR primers in the PCR reaction are pAAACAGAAGCACCAGTCGGTATTCA (SEQ ID NO:32:) and ATATGAATTCTCAGGTGCACGCACAGGTTGGCCGTA (SEQ ID NO:33:).
- a DNA product of 215 bp which encodes the C-terminus of mouse complement C1q-C subunit (see Petry et al., Eur. J.
- Biochem. (1992) 209:129 and Genbank Accession No. X66295) is isolated and digested with EcoRI.
- the two digested PCR products are ligated into p ⁇ 2(I) previously digested with AvrII and EcoRI as described above, creating pPL4-1.
- These steps create a human ⁇ 2(I) procollagen cDNA having the mouse complement C1q-C subunit C-terminus, which replaces the human ⁇ 2(I) procollagen C-propeptide and introduces a IEGR (SEQ ID NO:2:) recognition site for the protease Factor X a at the junction of the C-telopeptide and C-propeptide.
- the human ⁇ 2(I) procollagen cDNA containing ubiquitin in place of the endogenous N-propeptide and the C-terminus of complement C1q-C subunit instead of the endogenous C-propeptide is created by removing the 2850 bp XhoI/XhoI fragment from PL3-4 (described in section E), inserting this DNA fragment into PL4-1 (described in section F) digested with XhoI, and discarding the 2725 bp fragment, creating pM ⁇ 2(I).
- the XhoI fragment from pPL3-4 can insert itself into pPL4-1 in either orientation. The orientation which places the translation start codon toward the 5′ end of the construction is selected using DNA sequence analysis.
- pSV-SPORT1 (Life Technologies, Ind., Gaithersburg, Md.) is used as the expression vector for the mutated ⁇ 1(I)procollagen cDNA (pM ⁇ 1(I) from example 2D) and the mutated ⁇ 2(I) procollagen cDNA (pM ⁇ 2(I) from Example 2G).
- pSV-SPORT1 is digested with the restriction enzymes SalI and SspI.
- the fragment containing the mutated ⁇ 1(I) procollagen cDNA is ligated into pSV-SPORT1 at the SalI and SnaBI sites, creating PSV-M ⁇ 1(I).
- pM ⁇ 2(I) is digested with SalI and SmaI.
- the fragment containing the mutated ⁇ 2(I) procollagen is ligated into pSV-SPORT1 at the SalI and SnaBI sites, creating pSV-M ⁇ 2(I).
- Either pSV-M ⁇ 1(I) or pSV-M ⁇ 2(I) is co-transfected with pRSV neo into HT1080 cells (American Type Culture Collection, Rockville, Md.) using Lipofectamine Reagent (Life Technologies, Gaithersburg, Md.) and following the manufacturer's protocol for stable transfection of adherent cells.
- the mutated procollagen product from HT1080 cells transfected with either pSV-M ⁇ 1(I) or pSV-M ⁇ 2(I) is secreted into the medium as homotrimeric molecules.
- the medium is collected and protease inhibitors are added to a final concentration of 10 mM N-ethylmaleimide, 1 mM PMSF, and 25 mM EDTA.
- Ammonium sulfate is added to the medium to a final concentration of 30%, and the medium is stored at 4° C. for 16 hours.
- the medium is centrifuged at 4000 rpm for 10 minutes at 4° C.
- the pellet is resuspended in 50 mM Tris, pH 7.4, 150 mM NaCl, and protease inhibitors at the concentrations listed above, or in the appropriate buffer for cleavage of one or both of the propeptides from the collagen molecule.
- Recombinant human collagen produced as described in Example 3 is adjusted to a collagen concentration of 10 mg/ml by addition of 0.13 M phosphate buffer at pH 7.2 under conditions favoring fiber formation.
- the resulting suspension of fibrillar collagen is centrifuged at 10,000 ⁇ g to concentrate the collagen, which is subsequently rediluted to a concentration of 35 mg/ml by the addition of phosphate buffer.
- the resulting fibrillar collagen suspension is aliquotted into syringes for use in soft tissue augmentation.
- a physician attaches a 25-guage or smaller needle to a syringe containing the recombinant human fibrillar collagen suspension prepared as described above. After attaching the needle to the collagen-containing syringe, the physician injects the collagen subcutaneously into the dermis, using multiple serial punctures, to soft tissue sites in need of augmentation, such as acne scars and wrinkles. Collagen is injected to a particular soft tissue site until the previously depressed area is even with the surface of the surrounding normal skin.
- Recombinant human collagens are assayed and compared with purified human placental, bovine hide, and rat tail collagens for their ability to support gel contraction by human dermal fibroblasts.
- Recombinant human collagens are prepared as described in Example 3. Human collagen is purified from human placenta by extraction with 0.1 M acetic acid, followed by precipitation of type I collagen by the addition of 1 M NaCl. Bovine hide and rat tail collagens are commercially obtained in soluble form (e.g., Vitrogen).
- Rates of contraction are measured each day by placing the culture dish containing the contracted cell matrix over a template containing circles of varying diameter, then estimating the diameter of the contracted cell matrix by comparison with the circles on the template.
- Recombinant human collagens prepared as described in Example 2 are shown to promote fibroblast contraction at rates at least comparable to those obtained using rat tail, purified. human placental, and bovine hide collagens.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Animal Husbandry (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
- This is a continuation of and claims priority under 35 U.S.C.§ 120 to U.S. Ser. No. 08/278,774, filed Jul. 22, 1994, now U.S. Pat. No. 6,653,450, which is a continuation-in-part of U.S. Ser. No. 08/183,648, filed Jan. 18, 1994, now U.S. Pat. No. 5,667,839, which is a continuation-in-part of U.S. Ser. No. 08/011,643 filed Jan. 28, 1993, abandoned, all of which are incorporated herein by reference.
- The field of this invention is recombinant procollagens containing novel cleavage sites.
- Collagen has provided a number of commercial applications including use as a convenient substrate for cell culture, as well as in the manufacture of biocompatible materials (e.g., artificial skin) having a variety of therapeutic applications in humans. Commercially available collagens are primarily isolated from freshly killed farm animals (e.g., cows, pigs, chickens) in polymerized form or in soluble form derived by enzymatic or chemical treatment of polymerized collagen. However, polymerized collagens, and soluble collagens derived from polymerized collagens, are of limited usefulness due to the presence of natural crosslinks within the collagen. Furthermore, non-human collagens can provoke undesirable immune responses when administered to human subjects.
- As one alternative, human collagen can be purified from human sources such as human placenta, as described in U.S. Pat. No. 5,002,071 (Research Development Foundation) and in copending U.S. application Ser. No. 07/921,810 (Collagen Corporation). In addition to source limitations and the risk of contamination by human pathogens such as Hepatitis viruses and HIV, the methods for recovering collagen from these sources bias the type of collagen recovered. Furthermore, because collagen is derived from naturally crosslinked tissues, the collagen recovered is not entirely homogenous. Another approach to the production of human collagen is the expression of recombinant human collagen in the milk of transgenic animals, as described in copending U.S. application Ser. Nos. 08/183,648 and 08/011,643 (Collagen Corporation). However, this approach subjects the recombinant collagen to any host deficiencies in translational processing.
- The term collagen refers to a type of protein that encompasses a class of structurally related polypeptides consisting of helical collagen chains and homo- and heteromeric polymers thereof. Collagen chains often contain both long helical domains and non-helical extensions, or telopeptides. The helical domains comprise -(GXY)n— repeats, where X and/or Y are frequently proline or hydroxyproline.
- Collagen polypeptide chains are encoded by a number of related genes, See, Adams, S. L. Amer J Respir Cell and Mol Biol (1989) 1:161-168; Mayne and Brewton (1993) Current Opinion in Cell Biology 5:883-890; van der Rest and Bruckner (1993) Current Opinion in Structural Biology 3:430-436. Collagen-encoding transcripts are initially translated into procollagen chains which undergo a variety of post-translational events such as processing, secretion and assembly (e.g. disulfide exchange, prolyl residue hydroxylation, glycosylation, and crosslinking of the helical chains; see, for example, Prockop et al. (1984) New England J Med 3111:376-386) to form mature collagen chain helices. In addition, procollagens contain N- and C-terminal propeptides that facilitate collagen formation. See, for example, Lee et al. (1992) J Biol Chem 267, 24126-24133.
- Many of these post-translational events are catalyzed by enzymes thought to be expressed only in or by cells which naturally produce collagen. For example, the procollagen propeptides are cleaved from the procollagens by tissue-specific procollagen N- and C-terminal proteases. Accordingly, recombinant production of collagen has been severely restricted by the inability of conventional cellular expression systems to efficiently post-translationally modify procollagen to form functionally mature collagen.
- Site-specific proteolysis of unrelated fusion proteins is reported by Paul Carter in (1990), Protein Purification: From Molecular Mechanisms to Large-Scale Processes, p. 181-193, American Chemical Society Research Symposium #47; Brenner and Fuller (1992) PNAS 89:922-926; and Seeboth, et al. (1992) Appl Microbiol Biotechnol 37:621-625; Liu and Miller (1989) WO 89/12678. Chemical cleavage is described in Fontana and Gross (1986), Chapter 2 of In Practical Protein Chemistry—A Handbook, Darby, Ed; John Wiley and Sons, London.
- The invention provides recombinant procollagen chains having a natural collagen polypeptide chain separated from a propeptide by a non-natural site-specific proteolytic agent recognition site (i.e. the site is not naturally present at that location of a natural procollagen chain). The propeptide is often a C-terminal propeptide and, frequently, a natural procollagen C-terminal propeptide. Alternatively, the recombinant procollagen chains may further comprise a second propeptide separated from the opposite end of the natural collagen chain by a second non-natural site-specific proteolytic agent recognition site.
- A wide variety of propeptides and site-specific proteolytic agent recognition sites may be used. The propeptide is capable of increasing the yield of at least one of secreted procollagen (trimeric procollagen chains) or collagen monomers (trimeric collagen chains) from cells expressing procollagen chains comprising the propeptide, as compared with cells expressing the same collagen chains alone, without the propeptide. The non-natural site-specific proteolytic agent recognition site is generally selected to provide a substrate for a convenient site-specific proteolytic agent. The agent is commonly a protease or a chemical agent which selectively cleaves at accessible and preferentially labile peptide bonds. Where two site-specific proteolytic agent recognition sites and two propeptides are present, the recognition sites may have the same or different amino acid sequences with the same or different site-specific proteolytic agent affinities and specificities.
- The subject procollagen chains may be constructed such that the site-specific proteolytic agent cleavage site is a peptide bond that separates the collagen chain and/or the propeptide from the remainder of the procollagen chain. Alternatively, the cleavage site may be a peptide bond that separates, from the remainder of the procollagen chain, the collagen chain (or propeptide) joined to at least one amino acid which is not naturally present at that location of a natural collagen chain (or propeptide).
- The invention provides collagens produced by contacting the subject recombinant procollagen with site-specific proteolytic agents capable of selectively cleaving the procollagen chains at the site-specific proteolytic agent recognition sites, wherein the resulting chains comprise terminal peptides which may have non-natural amino acid sequences (i.e. not naturally present at that location of a natural collagen chain). The resulting collagen may be employed directly (e.g. to coat cell culture dishes or cultureware) or further polymerized and/or provided in sterile, nontoxic, biocompatible collagen compositions suitable for administration to humans.
- The invention also provides nucleic acids encoding the subject procollagen chains, as well as vectors and cells comprising such nucleic acids operably linked to transcription regulatory elements not naturally linked to such nucleic acids. The invention provides processes for the production of recombinant procollagen and/or collagen chains in and from such cells. The invention also provides methods of utilizing the resulting procollagen and collagen, for example, coating cultureware and augmenting localized tissue in a host by, for example, subcutaneous administration.
-
FIG. 1 shows a three-dimensional computer model of the N-terminal propeptide-telopeptide region of human procollagen type I (a triple helix of two α1 chains and one α2 chain). The structure was produced on a Silicon Graphics workstation using Biosym software. The energy minimized structure is produced after manual chain pull-ins to speed the process of computing the energy minimums. Points of cleavage with N-pro-peptidase are marked with a “▾”. -
FIG. 2 shows a three-dimensional computer model of the C-terminal propeptide-telopeptide region of human procollagen type I (a triple helix of two α1 chains and one α2 chain). The structure was produced on a Silicon Graphics workstation using Biosym software. The energy minimized structure is produced after manual chain pull-ins to speed the process of computing the energy minimums. Points of cleavage of the extra-helical peptide from the C-terminal pro-region are marked with a “▾”. In the two α1 chains, this is beforeGly 38; in the α2 chain, it is before Glu 27. -
FIG. 3 shows a three-dimensional computer model of the N-terminal propeptide-telopeptide region of a mutant human procollagen type I containing the DDDK insertion. The structure was produced on a Silicon Graphics workstation using Biosym software. The energy minimized structure is produced after manual chain pull-ins to speed the process of computing the energy minimums. The insertional loop members are marked with a “▾”. -
FIG. 4 shows the proteolytic cleavage site of the mutant human procollagen type I containing the DDDK insertion. Points of cleavage of N-propeptidase are marked with a “▾”. Regions in whichc the α1 chains are “coiled” are disignated with a “10”. - The invention provides recombinant procollagen chains comprising a natural collagen chain, a propeptide, and a non-natural site-specific proteolytic agent recognition site (i.e. not naturally present at that location of a natural collagen chain) located between the collagen chain and the propeptides.
- The propeptide increases the yield of at least one of secreted procollagen (trimeric procollagen chains) or collagen monomers (trimeric collagen chains) recoverable from cells expressing the subject recombinant procollagen chains, as compared with cells expressing the collagen chains alone, without the propeptide. Generally, the yield is enhanced by at least 50%, preferably at least about 100%, more preferably at least about 200%, and most preferably at least about 1,000% in at least one expression system.
- Collagen refers to a variety of helical arrays of collagen chains and includes both polymerized and monomeric collagen. The propeptides are believed to improve collagen and/or procollagen yields by facilitating or increasing at least one of proper expression, processing, secretion, or polymerization of the procollagen chain, the collagen chain, and/or a collagen monomer. The function of the propeptide is readily monitored by comparing the yields of recoverable collagen and/or procollagen with and without the presence of the propeptide in in vitro or in vivo expression systems including lysates, transformed or transfected cells (such as mammalian cells or yeast), transgenic animals, etc. Specific examples of assays for propeptides are described below.
- The propeptide may take a wide variety of forms and sizes: it may be a natural procollagen propeptide, or a propeptide not naturally present as a propeptide in a procollagen chain, as long as it provides the procollagen with the requisite collagen yield. Generally, propeptides are at least 10, preferably at least about 25, more preferably at least about 75, and most preferably at least about 200 amino acids in length. The propeptide is generally located at the C-terminus or N-terminus of the procollagen chain, or the procollagen chain may have propeptides at both termini. Where the recombinant procollagen chains contain both C- and N-terminal propeptides, the chains often comprise a second (and often non-natural) site-specific proteolytic agent recognition site located between the collagen chain and the second propeptide.
- Preferred procollagen chains comprise at least a C-terminal propeptide, frequently a natural C-terminal portion of a protein with collagen-like repeats and/or a helical, especially triple-helical, polymeric form, such as complement protein C1q-C, acetocholine esterase, or lung surfactant protein. Especially preferred are natural procollagen C-terminal propeptides, such as collagen Type I, II, III, IV, V and XI C-terminal propeptides. Preferred N-terminal propeptides comprise at least one globular domain and often consist essentially of a single globular domain. Especially preferred are natural procollagen N-terminal propeptides, such as collagen type I, II, III, IV, V, and XI N-terminal propeptides.
- After cleavage from the collagen chain, the propeptides are preferably purified out of the collagen composition. The propeptides are preferably selected such that, if small quantities of the propeptides remain in the collagen composition after processing, the residual propeptides do not interfere with the intended application of the resulting composition. For example, for in vivo use, the composition should not contain contaminants present in an amount sufficient to cause a toxic or immunogenic response or reaction in the patient.
- A wide variety of site-specific proteolytic agent recognition sites may be used. The recognition site is non-natural to a natural procollagen chain, meaning that the site occupies a portion of the procollagen chain not naturally occupied by the recognition site. Frequently, the site is not naturally present anywhere in the natural counterpart of the procollagen chain. The site generally comprises one or more amino acid residues or derivatives thereof. The recognition site may comprise a modified (e.g., methylated) residue, especially for some chemical proteolytic agents. These sites are selected to provide substrates for at least one convenient site-specific proteolytic agent, preferably a commercially available site-specific proteolytic agent. The precise site selection will depend on the selected expression system, the selected propeptide, and the availability of the site-specific proteolytic agent. For example, the site should provide a highly selective target for the selected site-specific proteolytic agent, such that the target site (or both target sites) is cleaved while minimizing hydrolysis of peptide bonds within the collagen chain.
- A large number of site-specific proteolytic agents and their recognition sites are known and/or commercially available. See, for example, Carter (1990, supra), Saito et al. (1987) J. Biochem 101, 123-134, etc. For example, a wide variety chemical cleavage agents and their recognition sites are known, e.g. hydroxylamine: N↓G; formic acid: D↓P; acetic acid: D↓P; cyanogen bromide: M↓; BNPS-skatole: W↓; o-iodosobenzoic acid: W↓; N-chlorosuccinimide: W↓; etc. Alternatively, natural or synthetic proteases (e.g. catalytic antibodies, etc.) may be used. Examples of proteases and their recognition sites include: chymotrypsin: W↓ and Y↓ and F↓; collagenase: P-X↓G-P, endoproteinase Lys-C: K↓; enterokinase: D-D-D-K↓ (SEQ ID NO: 1:), Factor Xa: I-E-G-R↓ (SEQ ID NO:2:); kallikrein: P—F—R↓; renin: Y-I-H—P—F—H-L↓L (SEQ ID NO:3:), H64A subtilisin BPN: A-A-H—Y↓ (SEQ ID NO:4:), thrombin: R-G-P—R↓ ( SEQ ID NO:5:); trypsin: R↓ and K↓; ubiquitin protein peptidase: ubiquitin↓; etc. A wide variety of methods may be used to increase the efficiency of cleavage at a target site (e.g. the provision of flanking poly-glycine peptides to enhance accessibility) and/or to reduce non-target site cleavage (e.g. optimizing concentration ratios and reaction conditions).
- Preferred site/site-specific proteolytic agent combinations yield a collagen product that is conveniently adapted to the ultimate intended application. For example, any residual non-natural terminal residues should not interfere with and, preferably, enhance the performance (e.g. the promotion of cell growth or adherence to coated cultureware) of the resulting collagen product vis-a-vis the natural collagen counterpart. For in vivo use, the resulting collagen should not be immunologically reactive in the host from which the collagen chain is derived. Generally, immunological non-reactivity is effected by minimizing the number of non-collagen chain amino acid residues which remain joined to the collagen chain after site-specific proteolytic agent cleavage. Preferred site/site-specific proteolytic agent combinations yield collagen chains with fewer than 75, preferably fewer than 25, more preferably fewer than 10, most preferably fewer than 5 and, especially, zero, non-natural collagen chain terminal amino acid residues. Hence, preferred sites and site-specific proteolytic agents provide cleavage at or near the junction with natural collagen chain residues.
- Where two site-specific proteolytic agent recognition sites and two propeptides are present, the site-specific proteolytic agent recognition sites may have the same or different amino acid sequences, with the same or different site-specific proteolytic agent affinities and specificities. The site-specific proteolytic agent recognition site(s) generally, but need not, abut both the collagen chain and respective propeptide; i.e. the subject procollagen chains may also have a natural or non-natural (i.e. not naturally present at that location of a natural procollagen chain) amino acid sequence between the site-specific proteolytic agent recognition site and the collagen chain, and/or between the site-specific proteolytic agent recognition site and the propeptide. Accordingly, depending on the selected recognition site, site-specific proteolytic agent, and presence or absence of residues separating the cleavage site from the collagen chain, the resulting (after cleavage) recombinant collagen chains may comprise one or both terminal peptides having a non-natural amino acid sequence. By way of example:
-
- for human α1(I) collagen, a preferred N-terminal peptide is NH2—X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15QLSYGYDEKSTGGISVP (SEQ ID NO:6:), where “X1—X15” is other than PGPPGPPGLGGNFAP (SEQ ID NO:7:); and a preferred C-terminal peptide is PPQEKAHDGGRYYRA(SEQ ID NO:8:) X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15, where “X1—X15” is other than DDANVVRDRDLEVDT (SEQ ID NO:9:);
- for human α2(I) collagen, a preferred N-terminal peptide is NH2—X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15QYDGKGVGLGP (SEQ ID NO:10:), where “X1—X15” is other than PGPPGPPGLGGNFAA (SEQ ID NO:11:); and a preferred C-terminal peptide is GGGYDFGYDGDFYRA(SEQ ID NO:12:)X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15, where “X1—X15” is other than DQPRSAPSLRPKDYE (SEQ ID NO: 13:);
- for human α1(II) collagen, a preferred N-terminal peptide is NH2—X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15QMAGGFDEKAGGAQMGVQM (SEQ ID NO:14:), where “X1—X15” is other than PGPPGPPGLGGNFAA (SEQ ID NO:15:); and a preferred C-terminal peptide is GPREKGPDPMQYMRA(SEQ ID NO:16:)X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15, where “X1—X15” is other than DEADSTLRQHDVEVD (SEQ ID NO:17:);
- for human α1(III) collagen, a preferred N-terminal peptide is NH2—X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15QYDSYDVKSGVAVG (SEQ ID NO:18:), where “X1—X15” is other than GICESCPTGPQNYSP (SEQ ID NO:19:); and a preferred C-terminal peptide is GIGGEKAGGFAPYYG(SEQ ID NO:20:)X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15, where “X1—X15” is other than DEPMDFKINTDEIMT (SEQ ID NO:21:).
- The invention provides recombinant collagen chains produced by contacting the subject recombinant procollagen chains with site-specific proteolytic agents capable of selectively cleaving the procollagen chain at site-specific proteolytic agent recognition sites. Useful collagen compositions produced by such methods may retain residual site-specific proteolytic agents, wherein the site-specific proteolytic agents are present at concentrations that may exceed 1 picogram, frequently exceed 1 nanogram, and more frequently exceed 1 microgram per gram of collagen protein. Resulting collagen compositions may be subjected to conditions known in the art to be conducive to higher-order polymerization of the collagen, for example, fibril formation. Monomeric or polymeric collagen compositions may be further subjected to a wide variety of manipulations depending on the intended application. For example, the collagen may be diluted in an solvent for optimal adsorption to solid substrates (e.g. glass or plastics such as polystyrene, polyethylene, polypropylene, acetate, nylon, etc.) useful in tissue or cell culture, or purified and sterilized (e.g. filter sterilization) for use in vivo, such as for tissue augmentation.
- The invention provides nucleic acids encoding the subject recombinant procollagen chains. These nucleic acids may have a wide variety of forms and sizes and frequently comprise non-coding sequences which facilitate transcription of the encoded procollagen chains. Constructs comprising such nucleic acids operably linked to transcription regulatory elements are spliced into replication and/or transfection vectors, which are then used to transfect/transform cells.
- Nucleic acids encoding the collagen chain portions (e.g. collA1, col1A2 and col3A1) and the site-specific proteolytic agent recognition portions of the subject nucleic acids are readily available, for example, through published sequences, including electronic databases (e.g., Genbank, the National Center for Biotechnology Information at the National Library for Medicine, etc.), through commercial vendors, through library hybridization with otherwise available collagen-encoding nucleic acids, or through known molecular cloning techniques. Materials and methods for constructing (e.g., recombinantly or synthetically) the subject procollagen-encoding nucleic acids, expression vectors, transformed and transfected cells, processes for producing a recombinant procollagen chain (including selection from a wide variety of cells, e.g., cultured mammalian cells such as fibroblasts, CHO cells, yeast, mammary gland cells of transgenic mammals, etc.), transfecting/transforming and culturing the cells under conditions suitable for the expression of the nucleic acid, and recovering and purifying recombinant procollagen chains are disclosed herein or otherwise known in the art. See, for example, Molecular Cloning, A Laboratory Manual (2nd Ed., Sambrook, Fritsch and Maniatis, Cold Spring Harbor), Current Protocols in Molecular Biology (Eds. Aufubel, Brent, Kingston, More, Feidman, Smith and Stuhl, Greene Publ. Assoc., Wiley-Interscience, NY, N.Y., 1992).
- In a preferred embodiment, construct design is effected by first preparing a three-dimensional model of a procollagen helix at the propeptide-telopeptide junction, then introducing amino acid substitutions that would allow cleavage with specific proteolytic enzymes. For example,
FIGS. 1 and 2 depict the structures of the N- and C-terminal propeptide-telopeptide regions of human type I procollagen, respectively. The structures are energy minimized and the native cleavage sites are marked. Molecular modeling is performed to ensure that the substitutions do not disrupt the folding of this region so as to inhibit processing, secretion, helical formation, or site-specific proteolytic agent accessibility. - Molecular constructs are then generated by either mutating procollagen-encoding cDNAs or splicing nucleic acids encoding the selected collagen chain with nucleic acids encoding the selected site-specific proteolytic agent recognition site. Mutation may be effected by site-directed mutagenesis, nucleotide insertion or substitution (e.g., by PCR-based mutagenesis) or replacement of oligonucleotides by cloning. The insertion site is preferably at or within 100, preferably within 30, more preferably within 10 nucleotides distal to the procollagen site-specific proteolytic agent cleavage site encoding sequence. The substituted nucleotides are within 60, preferably within 36, preferably within 18, nucleotides distal to the procollagen site-specific proteolytic agent cleave site encoding sequence. Preferred constructs additionally comprise nucleic acids including a promoter region necessary for the expression of the encoded procollagen in an appropriate host. Preferred promoters that are constitutive in cultured cells include cytomegalovirus (CMV), simian virus (SV), and Rous sarcoma virus (RSV) promoters. Preferred promoters for tissue-specific expression (e.g., in mammary gland cells) of transgenic animals include casein or acid whey protein promoters. Preferred promoters for expression in yeast include phosphoglycerol kinase (PKG), alcohol dehydrogenase (ADH), and galactose (GAL).
- The construct is then transfected into and expressed in a cellular expression system, preferably an expression system wherein the mutated procollagen is secreted. In less preferred embodiments, the recombinant PROcollagen is not sufficiently secreted, and recovery entails lysing the cells and centrifuging the lysate to remove cellular debris. In one embodiment, the cells are selected or engineered to express both the recombinant procollagen and a site-specific proteolytic agent capable of specifically cleaving the procollagen at the recognition site. Alternatively, the appropriate site-specific proteolytic agents are introduced in an amount sufficient to cleave the propeptides from the procollagen molecules prior to fibrillogenesis in the processing steps.
- Collagen chains are purified from the medium by methods known in the art. See, for example, Miller and Rhodes (1982) Methods in Enzymology 82:33-64; Sage and Bernstein (1982) Methods in Enzymology 82:96-127. Resulting collagen compositions may be sterilized, for example, by passage through 0.2 μm filters, (e.g., Millipore filters). Sterility may be confirmed by, for example, culturing aliquots on nutrient agar for at least 72 hours at 25 and 37° C. For therapeutic uses, it is desirable to ensure the non-toxicity, biocompatibility and non-immunogenicity of the resulting recombinant collagen compositions. For example, non-immunogenicity in humans is confirmed by dermal sensitivity testing.
- The invention provides a wide variety of applications of the subject recombinant procollagens and collagens in tissue and cell culture and therapy. For example, the subject procollagens and collagens are used to promote adhesion and growth of cells on a wide variety of solid substrates in various forms, such as slides, filaments, sheets, plates, flasks, bottles, fibers, etc., and compositions such as plastics, glass, metals, saccharide-based polymers, etc. The collagens provide a wide range of therapeutic applications such as use in biodegradable sutures, synthetic dermal skin, biodegradable hemostatic sponges, tissue augmentation (including modifying localized soft tissue appearance), etc.
- Tissue argumentation using collagen compositions has been thoroughly studied, documented, and implemented in wide-spread clinical settings. See, for example, DeLustro et al. (1986) J Biomed Mater Res, 20, 109-120; Elson M L (1989) J Dermatol Surg Oncol, 15, 301-303; Elson M L (1992) Am J Cosmetic Surg 9, 267-271; Klein et al. (1985) J Dermatol Surg Oncol, 11, 337-339; Klein et al. (1989) Geriatric Dermatology: Clinical Diagnosis and Practical Therapy, chapter 8, pp 47-49, Igaku-Shoin (publ) New York; Kligman A M (1988) J Dermatol Surg Oncol 14 (suppl I), 35-38; Kligman et al. (1986) J Dermatol Surg Oncol, 12, 351-357; Kligman et al. (1988) J Dermatol Surg Oncol, 14 (suppl I), 10-12; Knapp et al. (1977) Plas Reconstr Surg, 60, 398-405; Knapp et al. (1977) J Surg Res, 23, 96-105; Varnavides et al. (1987) Br J Dermatol 116, 199-206; etc.
- The following examples are offered by way of illustration and not by way of limitation.
- Three-dimensional models for the N- and C-terminal propeptide-telopeptide regions were performed as outlined above.
FIGS. 1 and 2 depict the energy minimized structures of the N- and C-terminal propeptide/telopeptide regions of human type I procollagen, respectively. Substitutions were then inserted at the N-terminal cleavage junction site to generate a non-natural site-specific proteolytic agent recognition site and new models prepared to determine their affects on procollagen folding. -
FIG. 3 depicts an N-terminal fragment containing a DDDK (SEQ ID NO:1:) insertion in all three chains, introducing a recognition and cleavage site for enterokinase into the propeptide-telopeptide junction region. As shown inFIG. 4 , the proteolytic cleavage site of this mutant is particularly accessible in the energy-minimized structure. - A. cDNA Clones Encoding Human α1(I) and α2(I) Procollagens
- A cDNA clone containing the entire coding region of human α1(I) procollagen is obtained from the Whitehead Institute (Cambridge, Mass.). The description of the cDNA is described in Stacy, et al, J Virol. 61: 2549 (1987). The nucleotide sequence of this clone (pHUC) is described in Tromp, et al, Biochem. J. 253:919 (1988), and also under Accession No. X07884 (Genbank, Los Alamos, N.Mex.). A cDNA clone (pSTL14) containing the entire coding region of human α2(I) procollagen is described in Lee, et al, J. Biol. Chem. 263:13414 (1988). The nucleotide sequence of human α2(I) procollagen is listed under Accession No. J03464 (Genbank), and the numbering system used assigns nt 1 to the transcription start point, according to Dickson et al., Nucl. Acids Res. 13:3427 (1985).
- B. Introduction of Cleavage Site into the Junction of N-Propeptide and N-Telopeptide of the Human α1(I) Procollagen cDNA
- A specialized cloning vector (pPL1) is created by isolating the AflIII/SspI region of Bluescript II KSM13+ from nucleotide position 1153 to 2850 (Stratagene Cloning Systems, La Jolla, Calif.) and inserting a double-stranded deoxyoligonucleotide polylinker containing the restriction sites (in order) HindIII, PvuII, DraIII, and BamHI. Using pHUC as a template, a 618 nt region of the 5′ end of the cDNA is amplified by the Polymerase Chain Reaction (Perkin Elmer Cetus, Norwalk, Conn., according to the manufacturer's instructions) using the oligodeoxynucleotide primer #1 ACGCCAAGCTTGGCTGCAGGTCGA (SEQ ID NO:22:) and primer #2 pCTGTTTATCATCGTCGGGAGCAAAGTTTCCTCC (SEQ ID NO:23:). The underlined nucleotide sequence in primer #2 codes for the amino acid recognition site (DDDK) (SEQ ID NO:1:) for the proteolytic enzyme enterokinase. The 610 nt DNA fragment generated by the PCR reaction is cleaved with the restriction enzyme HindIII, and cloned into pPL1 at the HindIII/PvuII sites, creating pPL1-1. Next, the PvuII/DraIII fragment from the human α1(I) procollagen cDNA (nt 858 to nt 1797) is cloned into pPL1-1 at the PvuII/DraIII sites, creating pPL1-2. The next step is to insert the PvuII/PvuII (nt 569 to nt858) fragment of the human α1(I) procollagen cDNA into pPL1-2 at the PvuII site, creating pPL1-3. This PvuII/PvuII fragment inserts itself into the vector in either orientation, so clones which contain the orientation identical to the human α1(I) procollagen cDNA are identified by DNA sequence analysis following the manufacturer's protocol (using Sequenase™ DNA sequencing kit by U.S. Biochemicals, Cleveland, Ohio, and the deoxynucleotide GAGTCACCCACCGACCAAGA (SEQ ID NO:24:) as the primer). The cDNA fragment from the human α1(I) procollagen cDNA from the DraIII site at position 1797 to the BamHI site at position 2886 is cloned into pPL1-3 at the DraIII/BamHI site, creating pPL1-4. The product of these steps is the continuous region of the human α1(I) procollagen cDNA from the 5′ end of the cDNA to the BamHI site at position 2886 with the introduction of a coding region for the amino acids DDDK, which is the amino acid recognition site for enterokinase.
- C. Introduction of Cleavage Site into the Junction of C-Telopeptide and C-Propeptide of the Human α1(I) Procollagen cDNA
- Another specialized cloning vector (pPL2) is created by the following procedure described above, but using a polylinker which contains the recognition sites for the restriction enzymes (in order) SalI, HindIII, BamHI, BspEII, and SspI. First, a fragment of the human α1(I) procollagen cDNA from the BamHI site at position 2886 to the BspEI site at position 3817 is cloned into the vector at the BamHI/BspEI site, creating pPL2-1. pPL2-1 is digested with the restriction enzymes Eco47III and XhoI, and the 106 bp fragment is discarded. A double-stranded deoxyoligonucleotide with the sequence GCTGGTTTCGACTTCAGCTTCCTCCC CCAGCCACCTCAAGAGAAGGCTCACGATGGTGGC CGCTACTACCGGGCTTGGGATGATGCCAATGTGGTTCGTGACCGTGACC (SEQ ID NO:25:) is inserted into pPL2-1 at the Eco47III/XhoI site, creating pPL2-2. This double-stranded deoxyoligonucleotide contains three additional (underlined) deoxynucleotides (as compared to the human α1(I) procollagen cDNA in this region) which code for the amino acid tryptophan. Next, a fragment of the human α1(I) procollagen cDNA from nt 3818 to 4611 is removed by the restriction enzymes BspEI and SspI and inserted into pPL2-2 at the BspEI/SspI site, creating pPL2-3.
- D. Assembly of Human α1(I) Procollagen cDNA with Non-Natural Cleavage Sites at the Propeptide-Telopeptide Junctions
- The human α1(I) procollagen cDNA containing additional nucleotide sequences within the cDNA, which code for additional amino acid(s) at the N-terminal propeptide-telopeptide and C-terminal telopeptide-propeptide junctions, is created by removal of the HindIII/BamHI fragment from pPL1-4 containing the 5′ region of the human α1(I) procollagen cDNA, as described in section B above, and inserting this fragment into the HindIII/BamHI sites of pPL2-3 containing the 3′ region of the human α1(I) procollagen cDNA, creating pM α1(I). This results in an α1(I) procollagen cDNA that codes for a polypeptide which can be cleaved at the N-terminal propeptide-telopeptide junction with enterokinase, leaving no additional terminal amino acids, and at the C-terminal telopeptide-propeptide with N-chlorosuccinimide, leaving the terminal amino acid tryptophan, according to the method described in Saito et al, J. Biochem. 101: 123 (1987).
- E. Use of Heterologous N-Propeptide and Introduction of Cleavage Site into the Junction of N-Propeptide and N-Telopeptide of the Human α2(I) Procollagen cDNA
- A specialized cloning vector (pPL3) is created as described in section B, but using a polylinker which contains the restriction sites (in order) SaII, SphI, PmII, MscI, and Sse83871. The human α2(I) procollagen cDNA is excised from pSTL14 using SphI and SmaI restriction enzymes. The resulting DNA fragment is treated with T4 DNA polymerase in the presence of deoxynucleotides to make a blunt end at the 5′ end of the cDNA. This fragment is subcloned into the Bluescript II vector at the EcoRV and Smal sites. The α2(I) procollagen cDNA fragment inserts itself into the vector in either orientation, so clones in which the Smal site is reconstituted are selected and given the name of p α2(I) . Polymerase Chain Reaction is performed according to the manufacturer's instructions (Perkin Elmer Cetus, Norwalk, Conn.) using Saccharomyces cerevisiae genomic DNA as template and the phosphorylated deoxyoligonucleotides pGTGGTATGCAAATTTTTGTCAAGACTTTGACTG (SEQ ID NO:26:) and pCCACCTCTCAATCTCAAGACT (SEQ ID NO:27:) as primers to isolate a fragment of the yeast gene UBI1 (ubiquitin) described in Oezkaynak et al, EMBO J.6: 1429 and listed under Accession No. X05728 (Genbank). The 232 bp DNA fragment is subcloned into the vector at the PmlI/MscI site, creating pPL3-1. This fragment inserts itself into the vector in either orientation, such that clones which contain the orientation identical to that of the human α2(I) procollagen cDNA are identified by digestion with the restrictin enzymes PmlI and MscI. A second PCR reaction is performed using p α2(I) DNA as the template and the two deoxyoligonucleotides pCCAGTATGATGGAAAAGGAGTT (SEQ ID NO:28:) and CGAGCACCTGCAGGACCAGTT (SEQ ID NO:29:) as the primers for this reaction. The 159 bp DNA fragment is digested with Sse83871 and subcloned into pPL3-1 at the MscI/Sse83871 sites, creating pPL3-2. p α2(I) is digested with SalI and PmlI, and the 199 nt fragment is isolated and inserted into pPL3-2 at the SalI and PmlI sites, creating pPL3-3. p α2(I) is digested with SalI and Sse8387I, and the 475 bp fragment is discarded. pPL3-3 is digested with SalI and Sse83871, and the 600 bp DNA fragment is isolated and cloned into p α2(I) at the SalI and Sse83871 sites, creating pPL3-4. This creates human α2(I) procollagen cDNA which contains the endogenous signal sequence, but codes for the yeast ubiquitin polypeptide, which replaces the endogenous N-propeptide. The human α2(I) procollagen can be cleaved at the N-propeptide-N-telopeptide junction with a ubiquitin-specific processing protease, as described in Tobias and Varshavsky, J. Biol. Chem. 266: 12021 (1991).
- F. Use of Heterologous C-Propeptide and Introduction of Cleavage Site into the Junction of C-Telopeptide and C-Propeptide of the Human α2(I) Procollagen cDNA
- α2(I) is digested with AvrII and EcoRI, and the 909 bp DNA fragment is discarded. Next, Polymerase Chain Reaction is performed according to the manufacturer's instructions using p α2(I) as template and the deoxyoligonucleotides TGGTCCTAGGGGCCCTGCTGGTCCTT (SEQ ID NO:30:) and pTCTACCTTCTATAGCCCTGTAGAAGTCTCCATCGTA (SEQ ID NO:31:) as primers. The underlined nucleotide sequence in the second primer codes for the amino acid recognition site (IEGR) (SEQ ID NO:02:) for Factor Xa A DNA product of 220 bp is isolated and then digested with AvrII. A second PCR reaction is performed using RT-PCR according to the manufacturer's instructions (Perkin Elmer Cetus, Norwalk, Conn.) using as template total RNA isolated from mouse spleen by the procedure of Han, et al, Biochem. 26, 1617 (1987). Random hexamers are used as primers for the reverse transcription of mouse RNA. The two PCR primers in the PCR reaction are pAAACAGAAGCACCAGTCGGTATTCA (SEQ ID NO:32:) and ATATGAATTCTCAGGTGCACGCACAGGTTGGCCGTA (SEQ ID NO:33:). A DNA product of 215 bp which encodes the C-terminus of mouse complement C1q-C subunit (see Petry et al., Eur. J. Biochem. (1992) 209:129 and Genbank Accession No. X66295) is isolated and digested with EcoRI. The two digested PCR products are ligated into p α2(I) previously digested with AvrII and EcoRI as described above, creating pPL4-1. These steps create a human α2(I) procollagen cDNA having the mouse complement C1q-C subunit C-terminus, which replaces the human α2(I) procollagen C-propeptide and introduces a IEGR (SEQ ID NO:2:) recognition site for the protease Factor Xa at the junction of the C-telopeptide and C-propeptide.
- G. Assembly of Human α2(I) Procollagen cDNA with Non-Natural Propeptide Domains and Non-Natural Cleavage Sites at the Propeptide-Telopeptide Junctions
- The human α2(I) procollagen cDNA containing ubiquitin in place of the endogenous N-propeptide and the C-terminus of complement C1q-C subunit instead of the endogenous C-propeptide is created by removing the 2850 bp XhoI/XhoI fragment from PL3-4 (described in section E), inserting this DNA fragment into PL4-1 (described in section F) digested with XhoI, and discarding the 2725 bp fragment, creating pM α2(I). The XhoI fragment from pPL3-4 can insert itself into pPL4-1 in either orientation. The orientation which places the translation start codon toward the 5′ end of the construction is selected using DNA sequence analysis. This results in a α2(I) procollagen cDNA which can be cleaved at the N-terminal propeptide-telopeptide junction with ubiquitin specific processing protease, and at the C-terminal telopeptide-propeptide junction with Factor Xa, leaving the terminal amino acids IEGR (SEQ ID NO:2:).
- pSV-SPORT1 (Life Technologies, Ind., Gaithersburg, Md.) is used as the expression vector for the mutated α1(I)procollagen cDNA (pM α1(I) from example 2D) and the mutated α2(I) procollagen cDNA (pM α2(I) from Example 2G). pSV-SPORT1 is digested with the restriction enzymes SalI and SspI. The fragment containing the mutated α1(I) procollagen cDNA is ligated into pSV-SPORT1 at the SalI and SnaBI sites, creating PSV-M α1(I). pM α2(I) is digested with SalI and SmaI. The fragment containing the mutated α2(I) procollagen is ligated into pSV-SPORT1 at the SalI and SnaBI sites, creating pSV-M α2(I).
- Either pSV-M α1(I) or pSV-M α2(I) is co-transfected with pRSV neo into HT1080 cells (American Type Culture Collection, Rockville, Md.) using Lipofectamine Reagent (Life Technologies, Gaithersburg, Md.) and following the manufacturer's protocol for stable transfection of adherent cells. The mutated procollagen product from HT1080 cells transfected with either pSV-M α1(I) or pSV-M α2(I) is secreted into the medium as homotrimeric molecules. After 24 hours, the medium is collected and protease inhibitors are added to a final concentration of 10 mM N-ethylmaleimide, 1 mM PMSF, and 25 mM EDTA. Ammonium sulfate is added to the medium to a final concentration of 30%, and the medium is stored at 4° C. for 16 hours. The medium is centrifuged at 4000 rpm for 10 minutes at 4° C. The pellet is resuspended in 50 mM Tris, pH 7.4, 150 mM NaCl, and protease inhibitors at the concentrations listed above, or in the appropriate buffer for cleavage of one or both of the propeptides from the collagen molecule. See the following sources for specific cleavage agents and reaction conditions: for enterokinase, Sigma Chemical Company, St. Louis, Mo.; for tryptophan chemical cleavage, Saito et al., J. Biochem. (1987) 101:1230134; for ubiquitin specific processing enzyme, Tobias and Varshavsky, J. Biol. Chem. (1991) 266:12021; for Factor Xa, New England Biolabs, Beverly, Mass.
- Recombinant human collagen produced as described in Example 3 is adjusted to a collagen concentration of 10 mg/ml by addition of 0.13 M phosphate buffer at pH 7.2 under conditions favoring fiber formation. The resulting suspension of fibrillar collagen is centrifuged at 10,000×g to concentrate the collagen, which is subsequently rediluted to a concentration of 35 mg/ml by the addition of phosphate buffer. The resulting fibrillar collagen suspension is aliquotted into syringes for use in soft tissue augmentation.
- A physician attaches a 25-guage or smaller needle to a syringe containing the recombinant human fibrillar collagen suspension prepared as described above. After attaching the needle to the collagen-containing syringe, the physician injects the collagen subcutaneously into the dermis, using multiple serial punctures, to soft tissue sites in need of augmentation, such as acne scars and wrinkles. Collagen is injected to a particular soft tissue site until the previously depressed area is even with the surface of the surrounding normal skin.
- Recombinant human collagens are assayed and compared with purified human placental, bovine hide, and rat tail collagens for their ability to support gel contraction by human dermal fibroblasts. Recombinant human collagens are prepared as described in Example 3. Human collagen is purified from human placenta by extraction with 0.1 M acetic acid, followed by precipitation of type I collagen by the addition of 1 M NaCl. Bovine hide and rat tail collagens are commercially obtained in soluble form (e.g., Vitrogen).
- Primary human dermal fibroblasts obtained from American Type Tissue Culture Collection are suspended in DMEM containing 10% (v/v) fetal calf serum at 1.0-1.4×105 cells/ml. One (1) milliliter of cell suspension and 2 ml of the same culture medium are added to 1 ml of recombinant collagen at a concentration of 2.5 mg/ml in 10 mM acetic acid. The cell suspension-collagen solution is poured into a 35-mm polystyrene petri dish (Costar) and incubated in a 37° C. tissue culture incubator in 5% CO2 for 5 days to allow contraction to occur.
- Rates of contraction are measured each day by placing the culture dish containing the contracted cell matrix over a template containing circles of varying diameter, then estimating the diameter of the contracted cell matrix by comparison with the circles on the template. Recombinant human collagens prepared as described in Example 2 are shown to promote fibroblast contraction at rates at least comparable to those obtained using rat tail, purified. human placental, and bovine hide collagens.
- All publications and patent applications cited in this specification are herein incorporated by reference, as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art, in light of the teachings of this invention, that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/720,831 US20050192428A1 (en) | 1993-01-28 | 2003-11-24 | Mutated recombinant collagens |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1164393A | 1993-01-28 | 1993-01-28 | |
US08/183,648 US5667839A (en) | 1993-01-28 | 1994-01-18 | Human recombinant collagen in the milk of transgenic animals |
US08/278,774 US6653450B1 (en) | 1993-01-28 | 1994-07-22 | Mutated recombinant collagens |
US10/720,831 US20050192428A1 (en) | 1993-01-28 | 2003-11-24 | Mutated recombinant collagens |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/278,774 Continuation US6653450B1 (en) | 1993-01-28 | 1994-07-22 | Mutated recombinant collagens |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050192428A1 true US20050192428A1 (en) | 2005-09-01 |
Family
ID=23066311
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/278,774 Expired - Lifetime US6653450B1 (en) | 1993-01-28 | 1994-07-22 | Mutated recombinant collagens |
US10/720,831 Abandoned US20050192428A1 (en) | 1993-01-28 | 2003-11-24 | Mutated recombinant collagens |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/278,774 Expired - Lifetime US6653450B1 (en) | 1993-01-28 | 1994-07-22 | Mutated recombinant collagens |
Country Status (3)
Country | Link |
---|---|
US (2) | US6653450B1 (en) |
EP (1) | EP0699752B1 (en) |
DE (1) | DE69531813D1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8852214B2 (en) | 2011-02-04 | 2014-10-07 | University Of Utah Research Foundation | System for tissue fixation to bone |
US8858577B2 (en) | 2010-05-19 | 2014-10-14 | University Of Utah Research Foundation | Tissue stabilization system |
US8945156B2 (en) | 2010-05-19 | 2015-02-03 | University Of Utah Research Foundation | Tissue fixation |
US9427309B2 (en) | 2012-07-30 | 2016-08-30 | Conextions, Inc. | Soft tissue repair devices, systems, and methods |
US9629632B2 (en) | 2012-07-30 | 2017-04-25 | Conextions, Inc. | Soft tissue repair devices, systems, and methods |
US10219804B2 (en) | 2012-07-30 | 2019-03-05 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US10390935B2 (en) | 2012-07-30 | 2019-08-27 | Conextions, Inc. | Soft tissue to bone repair devices, systems, and methods |
US10835241B2 (en) | 2012-07-30 | 2020-11-17 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US10973509B2 (en) | 2017-12-20 | 2021-04-13 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US11253252B2 (en) | 2012-07-30 | 2022-02-22 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US11547397B2 (en) | 2017-12-20 | 2023-01-10 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US11583384B2 (en) | 2014-03-12 | 2023-02-21 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US11696822B2 (en) | 2016-09-28 | 2023-07-11 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
WO2024029529A1 (en) * | 2022-08-02 | 2024-02-08 | 株式会社 UniBio | Collagen production method |
US11944531B2 (en) | 2012-07-30 | 2024-04-02 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US11957334B2 (en) | 2012-07-30 | 2024-04-16 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE59505585D1 (en) * | 1994-12-23 | 1999-05-12 | Roche Diagnostics Gmbh | Antigens and antibodies for the detection of collagen I |
GB9704305D0 (en) * | 1997-03-01 | 1997-04-23 | Univ Manchester | Procollagen assembly |
AU9312598A (en) * | 1997-09-10 | 1999-03-29 | Allegheny University Of The Health Sciences | Inhibitors of collagen assembly |
EP0913692A1 (en) * | 1997-10-31 | 1999-05-06 | Bayer Ag | An immunoassay for procollagen-III-C-terminal propeptide |
US6602980B1 (en) | 1998-06-19 | 2003-08-05 | Washington Research Foundation | Collagen type III synthetic peptides for collagen resorption assays |
AU4692199A (en) | 1998-06-19 | 2000-01-05 | Washington Research Foundation | Cartilage resorption assays |
US6348320B1 (en) | 1998-06-19 | 2002-02-19 | Washington Research Foundation | Cartilage resorption assays measuring type II collagen fragments |
US6916903B2 (en) | 1998-06-19 | 2005-07-12 | Washington Research Foundation | Collagen type III synthetic peptides for collagen resorption assays |
ES2229805T3 (en) * | 1999-06-17 | 2005-04-16 | Washington Research Foundation | CARTILAGO RESORTION TESTS. |
GB0413346D0 (en) * | 2004-06-15 | 2004-07-21 | Theryte Ltd | Treating cancer |
US20070224237A1 (en) * | 2006-03-24 | 2007-09-27 | Julia Hwang | Barbed sutures having a therapeutic agent thereon |
US20080081353A1 (en) * | 2006-09-29 | 2008-04-03 | Universite Laval | Production of recombinant human collagen |
US8933290B2 (en) * | 2007-06-26 | 2015-01-13 | Sofradim Production Sas | Mesh implant |
US9308068B2 (en) | 2007-12-03 | 2016-04-12 | Sofradim Production | Implant for parastomal hernia |
US9242026B2 (en) | 2008-06-27 | 2016-01-26 | Sofradim Production | Biosynthetic implant for soft tissue repair |
FR2949688B1 (en) | 2009-09-04 | 2012-08-24 | Sofradim Production | FABRIC WITH PICOTS COATED WITH A BIORESORBABLE MICROPOROUS LAYER |
US9732321B2 (en) | 2010-02-16 | 2017-08-15 | The General Hospital Corporation | Engineered craniofacial constructs with composite scaffold |
FR2972626B1 (en) | 2011-03-16 | 2014-04-11 | Sofradim Production | PROSTHETIC COMPRISING A THREE-DIMENSIONAL KNIT AND ADJUSTED |
FR2977789B1 (en) | 2011-07-13 | 2013-07-19 | Sofradim Production | PROSTHETIC FOR UMBILIC HERNIA |
FR2977790B1 (en) | 2011-07-13 | 2013-07-19 | Sofradim Production | PROSTHETIC FOR UMBILIC HERNIA |
CA2849052C (en) | 2011-09-30 | 2019-11-05 | Sofradim Production | Reversible stiffening of light weight mesh |
FR2985170B1 (en) | 2011-12-29 | 2014-01-24 | Sofradim Production | PROSTHESIS FOR INGUINAL HERNIA |
FR2985271B1 (en) | 2011-12-29 | 2014-01-24 | Sofradim Production | KNITTED PICOTS |
FR2994185B1 (en) | 2012-08-02 | 2015-07-31 | Sofradim Production | PROCESS FOR THE PREPARATION OF A POROUS CHITOSAN LAYER |
FR2995788B1 (en) | 2012-09-25 | 2014-09-26 | Sofradim Production | HEMOSTATIC PATCH AND PREPARATION METHOD |
FR2995778B1 (en) | 2012-09-25 | 2015-06-26 | Sofradim Production | ABDOMINAL WALL REINFORCING PROSTHESIS AND METHOD FOR MANUFACTURING THE SAME |
FR2995779B1 (en) | 2012-09-25 | 2015-09-25 | Sofradim Production | PROSTHETIC COMPRISING A TREILLIS AND A MEANS OF CONSOLIDATION |
CA2880380C (en) | 2012-09-28 | 2020-09-15 | Sofradim Production | Packaging for a hernia repair device |
FR3006578B1 (en) | 2013-06-07 | 2015-05-29 | Sofradim Production | PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY |
FR3006581B1 (en) | 2013-06-07 | 2016-07-22 | Sofradim Production | PROSTHESIS BASED ON TEXTILE FOR LAPAROSCOPIC PATHWAY |
EP3000489B1 (en) | 2014-09-24 | 2017-04-05 | Sofradim Production | Method for preparing an anti-adhesion barrier film |
EP3000432B1 (en) | 2014-09-29 | 2022-05-04 | Sofradim Production | Textile-based prosthesis for treatment of inguinal hernia |
EP3000433B1 (en) | 2014-09-29 | 2022-09-21 | Sofradim Production | Device for introducing a prosthesis for hernia treatment into an incision and flexible textile based prosthesis |
EP3029189B1 (en) | 2014-12-05 | 2021-08-11 | Sofradim Production | Prosthetic porous knit, method of making same and hernia prosthesis |
EP3059255B1 (en) | 2015-02-17 | 2020-05-13 | Sofradim Production | Method for preparing a chitosan-based matrix comprising a fiber reinforcement member |
EP3085337B1 (en) | 2015-04-24 | 2022-09-14 | Sofradim Production | Prosthesis for supporting a breast structure |
ES2676072T3 (en) | 2015-06-19 | 2018-07-16 | Sofradim Production | Synthetic prosthesis comprising a knitted fabric and a non-porous film and method of forming it |
EP3195830B1 (en) | 2016-01-25 | 2020-11-18 | Sofradim Production | Prosthesis for hernia repair |
EP3312325B1 (en) | 2016-10-21 | 2021-09-22 | Sofradim Production | Method for forming a mesh having a barbed suture attached thereto and the mesh thus obtained |
EP3398554A1 (en) | 2017-05-02 | 2018-11-07 | Sofradim Production | Prosthesis for inguinal hernia repair |
US11180541B2 (en) | 2017-09-28 | 2021-11-23 | Geltor, Inc. | Recombinant collagen and elastin molecules and uses thereof |
EP3653171A1 (en) | 2018-11-16 | 2020-05-20 | Sofradim Production | Implants suitable for soft tissue repair |
CA3136691A1 (en) | 2019-04-12 | 2020-10-15 | Geltor, Inc. | Recombinant elastin and production thereof |
BR112022014586A2 (en) | 2020-01-24 | 2022-09-13 | Geltor Inc | DIETARY COLLAGEN NOT DERIVED FROM ANIMALS |
CN114106150B (en) * | 2021-12-03 | 2022-08-16 | 江苏创健医疗科技有限公司 | Recombinant collagen, preparation method and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8708009D0 (en) | 1987-04-03 | 1987-05-07 | Clayton Found Res | Injectable soft tissue augmentation materials |
US5108919A (en) | 1988-06-24 | 1992-04-28 | Genentech, Inc. | Dna sequences encoding yeast ubiquitin hydrolase |
CA2121698C (en) * | 1991-10-23 | 2010-05-18 | Darwin J. Prockop | Synthesis of human procollagens and collagens in recombinant dna systems |
-
1994
- 1994-07-22 US US08/278,774 patent/US6653450B1/en not_active Expired - Lifetime
-
1995
- 1995-05-30 DE DE69531813T patent/DE69531813D1/en not_active Expired - Lifetime
- 1995-05-30 EP EP95108307A patent/EP0699752B1/en not_active Expired - Lifetime
-
2003
- 2003-11-24 US US10/720,831 patent/US20050192428A1/en not_active Abandoned
Cited By (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9451961B2 (en) | 2010-05-19 | 2016-09-27 | University Of Utah Research Foundation | Tissue stabilization system |
US8858577B2 (en) | 2010-05-19 | 2014-10-14 | University Of Utah Research Foundation | Tissue stabilization system |
US8945156B2 (en) | 2010-05-19 | 2015-02-03 | University Of Utah Research Foundation | Tissue fixation |
US9381019B2 (en) | 2011-02-04 | 2016-07-05 | University Of Utah Research Foundation | System for tissue fixation to bone |
US8852214B2 (en) | 2011-02-04 | 2014-10-07 | University Of Utah Research Foundation | System for tissue fixation to bone |
US10835241B2 (en) | 2012-07-30 | 2020-11-17 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US11253252B2 (en) | 2012-07-30 | 2022-02-22 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US9655625B2 (en) | 2012-07-30 | 2017-05-23 | Conextions, Inc. | Soft tissue repair devices, systems, and methods |
US10219804B2 (en) | 2012-07-30 | 2019-03-05 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US10390935B2 (en) | 2012-07-30 | 2019-08-27 | Conextions, Inc. | Soft tissue to bone repair devices, systems, and methods |
US10660642B2 (en) | 2012-07-30 | 2020-05-26 | Conextions, Inc. | Soft tissue repair devices, systems, and methods |
US10660643B2 (en) | 2012-07-30 | 2020-05-26 | Conextions, Inc. | Soft tissue repair devices, systems, and methods |
US9427309B2 (en) | 2012-07-30 | 2016-08-30 | Conextions, Inc. | Soft tissue repair devices, systems, and methods |
US11980360B2 (en) | 2012-07-30 | 2024-05-14 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US9629632B2 (en) | 2012-07-30 | 2017-04-25 | Conextions, Inc. | Soft tissue repair devices, systems, and methods |
US11446024B2 (en) | 2012-07-30 | 2022-09-20 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US11957334B2 (en) | 2012-07-30 | 2024-04-16 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US11944531B2 (en) | 2012-07-30 | 2024-04-02 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US11701218B2 (en) | 2012-07-30 | 2023-07-18 | Conextions, Inc. | Soft tissue to bone repair devices, systems, and methods |
US11583384B2 (en) | 2014-03-12 | 2023-02-21 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US11696822B2 (en) | 2016-09-28 | 2023-07-11 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US11547397B2 (en) | 2017-12-20 | 2023-01-10 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US10973509B2 (en) | 2017-12-20 | 2021-04-13 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
WO2024029529A1 (en) * | 2022-08-02 | 2024-02-08 | 株式会社 UniBio | Collagen production method |
Also Published As
Publication number | Publication date |
---|---|
EP0699752A2 (en) | 1996-03-06 |
DE69531813D1 (en) | 2003-10-30 |
EP0699752B1 (en) | 2003-09-24 |
EP0699752A3 (en) | 1997-03-05 |
US6653450B1 (en) | 2003-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6653450B1 (en) | Mutated recombinant collagens | |
Olsen et al. | Recombinant collagen and gelatin for drug delivery | |
CA2045869C (en) | Fusion proteins with immunoglobulin portions, the preparation and use thereof | |
US7253264B1 (en) | Immunoglobulin fusion proteins, their production and use | |
US5354736A (en) | Synthetic compounds and compositions with enhanced cell binding | |
EP0112849B1 (en) | A process for the preparation of chymosin | |
US6130318A (en) | hIL-4 mutant proteins used as antagonists or partial agonists of human interleukin 4 | |
JP2002523036A5 (en) | ||
JP2006223316A (en) | Recombinant fibrin chains, fibrin and fibrin-homologs | |
AU6031794A (en) | Production of human recombinant collagen in the milk of transgenic animals | |
JPH06504036A (en) | Expression of recombinant polypeptides with improved purification | |
EP0338634B1 (en) | Viper venom polypeptides and genetic expression | |
KR950001992B1 (en) | Method of producing peptides | |
US5935815A (en) | Process for micro biological production of proteins | |
JP2000125872A (en) | Trimer chimeric protein and collagen matrix containing chimeric protein | |
CA2273196A1 (en) | Isolated mammalian monocyte cell genes; related reagents | |
EP0497828B2 (en) | A process for endoproteolytically processing (precursor) proteins and for the (micro)biological production of proteins | |
EP0487617B1 (en) | Synthetic peptides that enhance cell binding | |
US5460955A (en) | Fibronectin purification vector | |
ATE253639T1 (en) | METHOD FOR PRODUCING PEPTIDES | |
JP3550409B2 (en) | Dipeptidyl aminopeptidase of dictyosterium | |
EP0119247A1 (en) | Production of mature proteins in transformed yeast | |
JP2002325584A (en) | Recombinant human iv type collagen peptide and method for producing the same | |
JPH09505998A (en) | DNA sequence encoding porcine pancreatic carboxypeptidase B | |
JPH0898693A (en) | Production of recombinant human matrilysin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ANGIOTECH PHARMACEUTICALS (US), INC., WASHINGTON Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ANGIOTECH BIOMATERIALS CORPORATION;REEL/FRAME:017325/0364 Effective date: 20051102 Owner name: ANGIOTECH BIOMATERIALS CORPORATION, CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:COHESION TECHNOLOGIES, INC.;REEL/FRAME:017325/0370 Effective date: 20041220 |
|
AS | Assignment |
Owner name: CREDIT SUISSE, AS COLLATERAL AGENT, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:ANGIOTECH PHARMACEUTICALS (US), INC.;REEL/FRAME:017448/0600 Effective date: 20060323 |
|
AS | Assignment |
Owner name: ANGIOTECH PHARMACEUTICALS (US), INC., WASHINGTON Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE;REEL/FRAME:018606/0616 Effective date: 20061211 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |